Drug Trial Radar · NCT07029945
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Biojiva LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is conducted in phases 1 and 2, focusing on assessing both safety (tolerability) and effectiveness (efficacy) of the treatment. Participants: Adults with geographic atrophy due to age-related macular degeneration. Treatment: BRX011 or Placebo is taken once daily as per the protocol. Duration: The study involves multiple visits over 96 weeks to monitor participants' health and response to treatment. Safety Monitoring: Regular checks for adverse events and health status to ensure participant well-being. Checks will include examination of vital signs, clinical labs, ocular exams, and ocular imaging. Primary Outcome Measure: Efficacy of BRX011 in the annual rate of change in the square root of GA area, as specified in the protocol.
Conditions
- Geographic Atrophy
Interventions
BRX011Drug
Subjects will ingest BRX011 orally, as capsules.
PlaceboDrug
Subjects will ingest Placebo orally, as capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual rate of change in the square root of GA areaTime frame: Baseline (Day 0) to Week 96
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Associated Retina Consultants - PHX
Gilbert, Arizona · Recruiting
Associated Retina Consultants
Phoenix, Arizona · Recruiting
Retina Specialists of Mississippi - Hattiesburg
Hattiesburg, Mississippi · Not yet recruiting
Sierra Eye Associates
Reno, Nevada · Not yet recruiting
Retina Associates of Cleveland - Beachwood
Beachwood, Ohio · Recruiting
Retina Associates of Cleveland
Cleveland, Ohio · Not yet recruiting
Retina Associates of Cleveland - Middleburg Heights
Middleburg Heights, Ohio · Not yet recruiting
Retina Research Institute of Texas
Abilene, Texas · Recruiting
Valley Retina Institute, PA
McAllen, Texas · Recruiting
Retina Research Center of Southern Utah
St. George, Utah · Not yet recruiting
Spokane Eye Clinic
Spokane, Washington · Not yet recruiting
Eye Clinic Albury Wodonga
Albury, New South Wales, Australia · Not yet recruiting
Nexus Eye Care
Baulkham Hills, New South Wales, Australia · Not yet recruiting
Retina & Macula Specialists
Hurstville, New South Wales, Australia · Not yet recruiting
Sydney Eye Hospital
Sydney, New South Wales, Australia · Not yet recruiting
Centre for Eye Research Australia (CERA)
East Melbourne, Victoria, Australia · Not yet recruiting
Retina Specialists Victoria
Rowville, Victoria, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.